Showing results (211-220 of 240) with videos related to

Sort By:
Pageof 24
Schizophrenia Bulletin|November 18, 2008
Supportive evidence for reduced expression of GNB1L in schizophreniaHiroki Ishiguro, Minori Koga, Yasue Horiuchi, et al.
Human Molecular Genetics|April 14, 2009
Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophreniaMinori Koga, Hiroki Ishiguro, Saori Yazaki, et al.
Plos One|February 21, 2008
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjectsEmmanuel S Onaivi, Hiroki Ishiguro, Jian-Ping Gong, et al.
Human Genome Variation|December 10, 2020
Rare single-nucleotide DAB1 variants and their contribution to Schizophrenia and autism spectrum disorder susceptibilityYoshihiro Nawa, Hiroki Kimura, Daisuke Mori, et al.
Nordic Journal of Psychiatry|June 26, 2020
Dyskinesia is most centrally situated in an estimated network of extrapyramidal syndrome in Asian patients with schizophrenia: findings from research on Asian psychotropic prescription patterns for antipsychoticsSeon-Cheol Park, Gyung-Mee Kim, Takahiro A Kato, et al.
Nordic Journal of Psychiatry|June 27, 2019
Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophreniaSeon-Cheol Park, Hong Seok Oh, Adarsh Tripathi, et al.
Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists|March 19, 2026
Pharmacoepidemiologic Trends and Factors Associated With Use and Dosing of Newer Antidepressants in 8357 Patients Across Asia: A Two-Decade PerspectiveJiangbo Ying, Qian Hui Chew, Tian-Mei Si, et al.
Annals of the New York Academy of Sciences|November 11, 2008
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depressionEmmanuel S Onaivi, Hiroki Ishiguro, Jian-Ping Gong, et al.
Neuropsychiatric Disease and Treatment|October 22, 2013
An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophreniaJinichi Hirano, Koichiro Watanabe, Takefumi Suzuki, et al.
Human Psychopharmacology|December 3, 2022
The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 studyChika Kubota, Toshiya Inada, Shih-Ku Lin, et al.
Pageof 24